Reviews and feature articleTherapeutic strategies to reduce asthma exacerbations
Section snippets
Prevention of severe asthma exacerbations
The purpose of asthma treatment is to attempt to achieve total asthma control.13, 14 Asthma control consists of 2 domains: current control (impairment), which reflects the day-to-day symptoms an asthmatic patient experiences and the burden imposed by these symptoms, and future risk, which consists of asthma exacerbations, irreversible decrease in lung function, and side effects from asthma medications.13 Thus the prevention of asthma exacerbations is an important component of establishing ideal
Conclusions
Severe asthma exacerbations can occur in any asthmatic patient and have potential long-term consequences with regard to a decrease in lung function. ISC treatment is very effective in reducing severe exacerbations when used as monotherapy, and the combination of an ICS with a LABA provides even more protection. In patients with a history of severe exacerbations, using ICS/LABA combinations, which contain the LABA formoterol, both as maintenance and rescue treatment has been shown to be superior
References (80)
- et al.
Costs of asthma in the United States: 2002-2007
J Allergy Clin Immunol
(2011) - et al.
Pharmacological management of mild or moderate persistent asthma
Lancet
(2006) - et al.
Asthma and increases in nonallergic bronchial responsiveness from seasonal pollen exposure
J Allergy Clin Immunol
(1983) - et al.
A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group
Chest
(1993) - et al.
Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma
J Allergy Clin Immunol
(2000) - et al.
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Lancet
(2002) - et al.
Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial
Lancet
(2001) Allergen-induced airway hyperresponsiveness
J Allergy Clin Immunol
(1988)- et al.
Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma
Pulm Pharmacol Ther
(2006) - et al.
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study
Lancet
(2006)
Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone
Respir Med
Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma
Chest
Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial
Lancet
Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
Lancet
The September epidemic of asthma exacerbations in children: a search for etiology
J Allergy Clin Immunol
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
J Allergy Clin Immunol
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis
J Allergy Clin Immunol
Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008
Ann Allergy Asthma Immunol
A prospective feasibility study of bronchial thermoplasty in the human airway
Chest
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice
Am J Respir Crit Care Med
Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma
Am J Respir Crit Care Med
Deaths from asthma in Victoria: a 12-month survey
Med J Aust
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group
Am J Respir Crit Care Med
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group
N Engl J Med
The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis
Am J Respir Crit Care Med
Community study of role of viral infections in exacerbations of asthma in 9-11 year old children
BMJ
Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study
BMJ
Severe exacerbations and decline in lung function in asthma
Am J Respir Crit Care Med
Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma—summary report 2007
J Allergy Clin Immunol
Global strategy for asthma management and prevention: GINA executive summary
Eur Respir J
Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics
Am Rev Respir Dis
Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics
Eur Respir J
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial
Am J Respir Crit Care Med
Use of inhaled corticosteroids in pediatric asthma
Pediatr Pulmonol Suppl
Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children
J Allergy Clin Immunol
Long-term inhaled corticosteroids in preschool children at high risk for asthma
N Engl J Med
Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents
J Pediatr
Biomarkers predicting response to corticosteroid therapy in asthma
Treat Respir Med
Exacerbations of asthma without sputum eosinophilia
Thorax
Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation
J Allergy Clin Immunol
Cited by (44)
RSV infection-elicited high MMP-12–producing macrophages exacerbate allergic airway inflammation with neutrophil infiltration
2021, iScienceCitation Excerpt :Asthma is a chronic airway inflammatory disease characterized by wheezing and increasing airway hyperresponsiveness (AHR) with allergic airway inflammation that promotes persistent physiological and structural remodeling events in the lungs (Galli et al., 2008). Several environmental allergens and/or viruses are known to trigger and exacerbate asthma via their effects on innate and adaptive immune cells (Jackson et al., 2011; O'Byrne, 2011). For example, dendritic cells in the airways induce sensitization to allergens, leading to the development of IL-4-, IL-5-, and IL-13-induced Th2-dependent airway inflammation (Lambrecht et al., 2000; van Rijt et al., 2005).
Antiviral and anti-inflammatory activity of budesonide against human rhinovirus infection mediated via autophagy activation
2018, Antiviral ResearchCitation Excerpt :Despite tremendous efforts to develop effective antiviral drugs for HRV infection, no treatment is currently available. Several medications have been used for the prevention of asthma exacerbation (O'Byrne et al., 2001; O'Byrne, 2011; Busse et al., 2001; Hanania et al., 2011). Budesonide is a corticosteroid, which can be used in combination with a long-acting beta agonist such as formoterol to prevent exacerbation of asthma and symptoms of common cold (Davies et al., 2011).
Retrospective cohort analysis of healthcare claims in the United States characterising asthma exacerbations in paediatric patients
2016, World Allergy Organization JournalCitation Excerpt :Asthma has been estimated to affect up to 10 % of children in the US [1]. Furthermore, the prevalence of uncontrolled asthma in children remains high despite widespread availabilityy of effective controller medications [2–5]. Lack of adherence to maintenance therapies such as inhaled corticosteroids, may lead to poor asthma control, particularly in older children [6].
Design and structure–activity relationships of novel inhibitors of human rhinovirus 3C protease
2016, Bioorganic and Medicinal Chemistry LettersTiming is everything: Targeting IgE to reduce asthma exacerbation risk
2015, Journal of Allergy and Clinical Immunology
Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MD